Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 79.27%
As of Thursday, July 23, China SXT Pharmaceuticals, Inc.’s SXTC share price has dipped by 79.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: China SXT Pharmaceuticals, Inc. (SXTC)
China SXT Pharmaceuticals, Inc. SXTC
$4.54
-0.59
-11.50%
August 19, 2026 4:00:00 PM
EST
Volume: 429,031
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Commentary & Analysis
Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 84.08%
As of Thursday, July 23, China SXT Pharmaceuticals, Inc.’s SXTC share price has dipped by 84.08%, which has investors questioning if this is right time to buy.Tudor Pop
Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 31.34%
As of Wednesday, July 22, China SXT Pharmaceuticals, Inc.’s SXTC share price has dipped by 31.34%, which has investors questioning if this is right time to buy.Michael Rose
Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 19.22%
As of Wednesday, July 22, China SXT Pharmaceuticals, Inc.’s SXTC share price has dipped by 19.22%, which has investors questioning if this is right time to buy.Tudor Pop
Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Up 11.11%
As of Tuesday, July 21, China SXT Pharmaceuticals, Inc.’s SXTC share price has surged by 11.11%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | SXTC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.5 | $618.0 | 1% |
|
| Shares Out (Mil) | na | 44.8 | na |
|
| Institutional Ownership | 22.4% | 85.3% | 11% |
|
| Float (Mil) | 0.4 | 47.4 | 1% |
|
| Beta | 1.89 | 0.70 | 91% |
|
| Avg Daily Volume (000s) | 3,238 | 390 | 88% |
|
| Price Change (52-week) |
(100.0%) | 68.6% | 0% |
|
| Growth | SXTC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (25.5%) | 6.7% | 1% |
|
| Net Income (5yr) | (18.1%) | (1.6%) | 22% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SXTC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $291 | 2% |
|
| Net Income (TTM) (Mil) | ($6) | ($11) | 32% |
|
| EPS (TTM) | na | ($0.700) | na |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($6) | 26% |
|
| Net Cash Flow (TTM) (Mil) | $10 | $5 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 16% |
|
| Enterprise Value (Q1) (Mil) | ($26) | $450 | 1% |
|
| Valuation | SXTC | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SXTC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 21.9% | 67.0% | 24% |
|
| Net Margin | (545.2%) | (2.3%) | 1% |
|
| ROA | (22.0%) | (22.4%) | 20% |
|
| ROE | (27.5%) | (20.2%) | 20% |
|
| Liabilities to Assets | 14.5% | 32.2% | 9% |
|
| F-Score | 2 | 3 | na |
|
China SXT Pharmaceuticals, Inc. did not pass any screens on 8/20/2026.
